Cai Qian is a PhD candidate (since September 2024) in Interventional Ultrasound at the First Medical Center of the Chinese PLA General Hospital, Beijing, China. Research interests include superficial organ and interventional ultrasound, percutaneous ablation and sclerotherapy for hepatic hemangioma, ablation-related complications and infection control, and thermal ablation–tumor immunology (post-ablation fever/prognosis; adoptive NK cell therapy combined with ablation for hepatocellular carcinoma). Cai has published or has accepted four first-author SCI-indexed papers (total IF 30.8), leads a doctoral innovation project (50,000 RMB), and has filed three Chinese invention patent applications.